Robert W. Baird analyst Joel Beatty maintained a Buy rating on Argenx Se (NASDAQ:ARGX) on Monday, setting a price target of $333, which is approximately 24.35% above the present share price of $267.79.
Beatty expects Argenx Se to post earnings per share (EPS) of -$0.81 for the second quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Moderate Buy rating of shares in Argenx Se, with an average price target of $309.86.
The analysts price targets range from a high of $400 to a low of $230.07.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $158.16 million and a net profit of -$11.17 million. The company's market cap is $13.74 billion.
According to TipRanks.com, Robert W. Baird analyst Joel Beatty is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 9.3% and a 51.38% success rate.
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.